Exelixis (EXEL) Tax Provisions (2010 - 2026)
Exelixis (EXEL) posted quarterly Tax Provisions of $57.2 million for Q2 2026, up 24.19% year-over-year from $46.1 million in Q2 2025, and up 601.23% quarter-over-quarter from $8.2 million in Q1 2026.
Exelixis (EXEL) Tax Provisions (2010 - 2026) Analysis & Trends
Exelixis' Tax Provisions history runs 14 years deep, the most recent figure standing at $57.2 million for Q2 2026.
- In Q2 2026, Tax Provisions rose 24.19% year-over-year to $57.2 million; the TTM figure through Apr 2026 stood at $169.8 million (down 12.71% YoY), while the FY2026 annual figure was $158.6 million, down 1.08% from the prior year.
- Tax Provisions for Q2 2026 stood at $57.2 million, up from $8.2 million in the prior quarter.
- The five-year high for Tax Provisions was $66.7 million in Q2 2024, with the low at -$1.3 million in Q4 2022.
- The 5-year median for Tax Provisions is $18.8 million (2022), against an average of $28.1 million.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions slumped 105.49% in 2022, then surged 1497.21% in 2023.
- Exelixis' Tax Provisions stood at -$1.3 million in 2022, then soared by 1497.21% to $17.5 million in 2023, then surged by 109.93% to $36.8 million in 2024, then surged by 59.96% to $58.8 million in 2025, then dropped by 2.74% to $57.2 million in 2026.
- Business Quant data shows EXEL's Tax Provisions at $57.2 million in Q2 2026, $8.2 million in Q1 2026, and $58.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 50.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 50.63 Mn |
| Apr 3, 2026 | 57.22 Mn |
| Jan 2, 2026 | 8.16 Mn |
| Oct 3, 2025 | 58.84 Mn |
| Jul 4, 2025 | 45.57 Mn |
| Apr 4, 2025 | 46.07 Mn |
| Jan 3, 2025 | 44.91 Mn |
| Sep 27, 2024 | 36.78 Mn |
| Jun 28, 2024 | 66.73 Mn |
| Mar 29, 2024 | 11.95 Mn |
| Dec 29, 2023 | 17.52 Mn |
| Sep 29, 2023 | 4.78 Mn |
| Jun 30, 2023 | 19.21 Mn |
| Mar 31, 2023 | 8.25 Mn |
| Dec 30, 2022 | -1.25 Mn |
| Sep 30, 2022 | 18.83 Mn |
| Jul 1, 2022 | 17.84 Mn |
| Apr 1, 2022 | 16.66 Mn |
| Dec 31, 2021 | 22.86 Mn |
| Oct 1, 2021 | 15.06 Mn |